A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
about
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerParaneoplastic thrombocytosis: the secrets of tumor self-promotionTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyThe role of the T cell in age-related inflammationStromal characteristics may hold the key to mammographic density: the evidence to dateSiltuximab (CNTO 328): a promising option for human malignanciesTargeted immune therapy of ovarian cancerImmunotherapy for metastatic renal cell carcinoma.Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migrationEvaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literatureMicroenvironmental regulation of therapeutic response in cancerChronic inflammation and cytokines in the tumor microenvironment.Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapyContribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor MicroenvironmentNovel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmClinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma.New insights into the biology of renal cell carcinomaTumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinomaProcess of hepatic metastasis from pancreatic cancer: biology with clinical significance.Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.Trial Watch: Monoclonal antibodies in cancer therapyAnti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation.The immune system in the pathogenesis of ovarian cancer.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.Inflammation: what role in pediatric cancer?Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.Interleukins in glioblastoma pathophysiology: implications for therapy.Interleukin-6--a key regulator of colorectal cancer development.Monoclonal antibodies in oncology therapeutics: present and future indications.Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.Clinical development of siltuximab.
P2860
Q26769917-DB0C9779-6D8C-407F-8BB2-3CA4A832D42BQ26825427-C865B611-06C3-44AB-B5D9-E53B9A60715BQ26993238-55CF2ABC-D701-4C31-AB76-C98527DF5085Q27026492-6339636E-D8C3-4039-87FB-A2EEA2798D6AQ28066162-0A4AAF1F-4E81-4D1B-9B99-24B53D90AAB7Q28082572-EC39C5EA-7E65-47A9-A6DB-777BB3DBD901Q28082828-DBA6251B-F798-4C69-9541-2CD9EEB93700Q30234458-11C2B245-E582-4068-A3B5-79EDC4CEC786Q30660919-5C9AD89D-338C-4A5E-A9E2-07EE0970888EQ33411075-7681F331-0EDE-44B2-8E2D-C983DA84ED63Q33628202-D2143469-5476-4B99-9FE0-762A7E0F32AEQ33654609-8DA897B2-68A2-4707-B255-D0559101A907Q33678275-9A129F5D-00A8-4837-8DE1-D0490F250F4BQ33866426-1F393E1A-0124-4470-8E42-638C21616046Q34153199-2647A4FA-5847-422B-AD38-F0B3E48FFF68Q34636002-39288FA0-17FE-48FF-9807-B2E021024A25Q35003674-4201A674-3841-4D4B-AFE4-5F479E30B96AQ35064011-D06832F1-F769-443E-A9F6-D5C429554DF7Q35180400-8131C414-DCF5-49E4-84E3-9002185AAC3AQ35582297-8966D809-870E-4835-8DE4-E312D90570CFQ35674197-A2FE1996-C966-4E5E-ABE5-2DF3D3BF655DQ35739397-FAA9043C-3420-48E5-9A49-267493C1DC78Q35946548-048C525D-2DE6-4E8F-96F1-3E590FB83E2BQ36038408-27DE1AB7-9B60-4E43-A3E9-87FF6E320D16Q36356086-CB40D3D9-4EAF-4A2F-BC52-3A3493030658Q36579912-E4A7846C-7073-488E-B024-1C981EB2C104Q36632887-085FFF2F-353B-4E19-A0DD-2BFB3CA83799Q36759538-B3BBDFA4-B5AA-4C95-B600-040B5E44EABDQ37274132-F47324E5-2B92-43E1-87B3-DFB0A3AFD695Q37582274-FE88C881-3288-4501-AB83-591FA86F1FB6Q37613407-10964C73-33E4-4B67-8691-D4084FA870F2Q37722551-69C38655-28BC-4438-81D2-E204964B7049Q37967667-5CC3FFE0-B8B8-447F-B80E-A834D1708382Q38042361-A1F8CD7D-9C30-4BB4-89E3-26B922F86697Q38051761-84E2C221-01BE-4191-A61F-B8E0027BEBB1Q38058510-5DA49AED-3C7F-405B-A383-95466449651BQ38071374-B1C6920E-C261-4448-8CE8-50ECC1FC2749Q38162129-C3142CC7-719D-44CB-8D0C-3ACEC1D44EC3Q38238365-A30E6D5E-C084-45B2-AF30-6512C3C853A6Q38489678-3D2CD501-0D0B-44C1-9338-90B58A4FA562
P2860
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@ast
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@en
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@nl
type
label
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@ast
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@en
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@nl
prefLabel
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@ast
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@en
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@nl
P2093
P2860
P356
P1476
A phase I/II study of siltuxim ...... n metastatic renal cell cancer
@en
P2093
U Prabhakar
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605872
P407
P577
2010-08-31T00:00:00Z
P5875
P6179
1050710195